TRINETRA › Sectors › Healthcare
Jubilant Pharmova Limited (JUBLPHARMA) — share price, P/E and fundamentals
Jubilant Pharmova Limited (NSE: JUBLPHARMA) closed at ₹925.60 on 30 Oct 2026, -14.3% over one year, against a 52-week range of ₹786.05 – ₹1,184.80.
In the quarter ended 30 Jun 2026 (consolidated, filed 10 Aug 2026) it reported revenue of ₹2,229 cr and net profit of ₹57 cr, a 2.5% net margin; revenue grew 17.3% and profit fell 44.1% year on year.
On four consecutive filed quarters its trailing P/E is 41.5; since 16 May 2025 its own P/E has ranged from 17.7 to 48.2 (median 23.0), and today's reading is higher than 90% of those 360 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 3.2%, ROCE 4.3%, debt-to-equity 0.45, Piotroski F-score 4 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 8% of 63 sector peers; PBT margin higher than 8% of 63 sector peers; ROE higher than 11% of 63 sector peers.
Key figures
| Last close | ₹925.60 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -13.0% / -2.1% / -14.3% |
| 52-week low – high | ₹786.05 – ₹1,184.80 |
| Market capitalisation | ₹14,624 cr |
| Trailing P/E | 41.5 |
| Price / book | 2.06 |
| EV / EBITDA | 13.5 |
| Earnings yield | 2.4% |
| TTM EPS | ₹22.28 |
| TTM net profit | ₹352 cr |
| Quarter revenue | ₹2,229 cr |
| Quarter net profit | ₹57 cr |
| Net margin | 2.5% |
| Revenue growth (YoY) | +17.3% |
| Profit growth (YoY) | -44.1% |
| Return on equity | 3.2% |
| ROCE | 4.3% |
| Debt / equity | 0.45 |
| Current ratio | 1.62 |
| Free cash flow | ₹-222 cr |
| Piotroski F-score | 4 / 9 |
| Average daily turnover (50 days) | ₹17.5 cr |
Against Healthcare peers
| Metric | JUBLPHARMA | Peer median | Percentile |
|---|---|---|---|
| Net margin | 2.53 | 12.89 | 8 |
| PBT margin | 3.88 | 17.68 | 8 |
| ROE | 3.19 | 13.87 | 11 |
| ROCE | 4.33 | 17.26 | 8 |
| Debt / equity | 0.45 | 0.11 | 88 |
| Cash conversion | 3.09 | 1.25 | 95 |
| Trailing P/E | 41.54 | 43.26 | 44 |
| P/B | 2.06 | 6.02 | 5 |
Questions
What is the P/E ratio of Jubilant Pharmova Limited?
Jubilant Pharmova Limited's trailing P/E is 41.5, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 16 May 2025 its P/E has ranged 17.7–48.2.
What were Jubilant Pharmova Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Jubilant Pharmova Limited reported revenue of ₹2,229 cr and net profit of ₹57 cr (consolidated), filed with the exchange on 10 Aug 2026.
What is Jubilant Pharmova Limited's ROE?
Return on equity is 3.2% based on the balance sheet dated 31 Mar 2026.
Does Jubilant Pharmova Limited have debt?
Debt-to-equity is 0.45 on the balance sheet dated 31 Mar 2026.
What is JUBLPHARMA's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, JUBLPHARMA traded between ₹786.05 and ₹1,184.80.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.